GLP-1
CagriSema
SaveA fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 RA) developed by Novo Nordisk, targeting weight loss through dual hormonal pathways.
Quick verdict
Phase III data shows ~25% mean weight loss, rivaling surgical outcomes. Regulatory submission expected. Could become a best-in-class obesity treatment.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
The REDEFINE Phase III program reported approximately 25% mean body weight loss at 68 weeks, exceeding semaglutide 2.4 mg monotherapy. The dual mechanism targets both GLP-1 and amylin receptors for additive appetite suppression.
Benefits
- ~25% mean weight loss in Phase III trials
- Dual-mechanism approach exceeding GLP-1 monotherapy
- Once-weekly subcutaneous injection
Dosage notes
Fixed combination of cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly in Phase III.
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
Who should be cautious
Not yet approved. GI tolerability burden may be higher than either component alone. Cost and access will be considerations.
What this page cannot tell you
Phase III results are strong but regulatory approval is still pending. Long-term weight maintenance data is not yet available.
Leaderboard scores
- Weight loss85
Write a review
Sign in to write a review.